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Multiple observations in preclinical and clinical studies support a role for the immune system in controlling tumor growth and
progression.Variouscomponentsoftheinnateandadaptiveimmuneresponseareabletomediatetumorcelldestruction;however,
certain immune cell populations can also induce a protumor environment that favors tumor growth and the development of
metastasis. Moreover, tumor cells themselves are equipped with various mechanisms that allow them to evade surveillance by
the immune system. The goal of cancer vaccines is to induce a tumor-speciﬁc immune response that ultimately will reduce
tumor burden by tipping the balance from a protumor to an antitumor immune environment. This review discusses common
mechanisms that govern immune cell activation and tumor immune escape, and some of the current strategies employed in the
ﬁeld of cancer vaccines aimed at enhancing activation of tumor-speciﬁc T-cells with concurrent reduction of immunosuppression.
1.Introduction
The role of the immune system in limiting tumor growth,
designated as cancer immunosurveillance [1], has been ﬁrst
elucidated in mouse models of immune deﬁciency charac-
terized by a high incidence of spontaneous and chemically
induced tumors [2]. Those studies have identiﬁed several
components of the innate and adaptive immune response
being responsible for tumor elimination, including αβ and
γδ T-cells [3], and NK cells [4]. Reinforcing the role of cyto-
toxic T lymphocytes (CTLs) in the eradication of malignant
cells, transgenic mice deﬁcient in perforin, a component of
the cytolytic granules of T and NK cells, are more susceptible
to spontaneous and chemically induced tumors than their
wild type counterparts [5]. In humans, evidence on the
role of the immune system in limiting tumor growth and
progression is linked to observations indicating a positive
correlation between the presence of tumor inﬁltrating CD8+
T-cells and good prognosis in various types of cancer. In
colorectal cancer, for example, signiﬁcantly higher levels of
early memory and eﬀector memory CD8+ T-cell inﬁltrates
positively correlate with good clinical outcome, deﬁned as
absence of metastatic invasion, less advanced pathological
stage, and increased survival [6, 7]. Similarly, the presence
of intraepithelial tumor inﬁltrating CD8+ T-cells has been
associated with the lack of tumor metastases in the draining
lymph nodes of cervical cancer patients [8]. In non-small
cell lung carcinoma patients, increasing numbers of tumor
inﬁltrating CD8+, CD20+, and CD4+ T lymphocytes have
also been shown to signiﬁcantly correlate with improved
disease-speciﬁc survival [9]. Altogether, these observations
support a role for the immune system in controlling tumor
burden and form the rationale for the development of
vaccine-based interventions against cancer that rely on the
stimulation of an eﬀective antitumor immune response in
the host.
The immune system, however, has two paradoxical roles
in cancer. While various components of the innate and
adaptive immune response are able to mediate tumor cell
destruction, speciﬁc types of immune cells can also induce
a protumor environment that favors tumor growth and the
development of metastasis [10]. Among the latter are, for
example, regulatory T (Treg) cells [11, 12], tumor associated
macrophages(TAM)[13,14],andtype2helperCD4+(Th2)2 Journal of Biomedicine and Biotechnology
T-cells [15,16].Thesevariousimmunecellshavebeenshown
to accumulate at the site of the tumor, negatively impacting
the establishment of antitumor T-cell responses, that is,
creating an immunosuppressive tumor environment.
Cancer cells themselves are also equipped with mecha-
nisms that allow them to evade recognition by the immune
system or to negatively aﬀect the functionality of eﬀector
T-cells. In order to avoid immune recognition, tumor
cells have been shown to downregulate antigen expression,
components of the antigen-processing and presentation
machinery, and expression of major histocompatibility
complex (MHC) molecules [17]. Decreased expression of
costimulatory molecules of crucial importance to T-cell
activation, and enhanced surface expression of molecules
that negatively regulate activation of T-cells, such as PD-
L1/B7-H1 and B7-H4, have also been demonstrated in
various types of tumors [18–20]. Cancer cells can also
restrain the function of the immune system by secreting a
milieuofsolublefactorsthatultimatelyinhibittheactivation,
proliferation, and diﬀerentiation of the various components
of the immune response. Among these molecules are TGF-
β [21], IL-10 [22], IL-13 [23], and VEGF [24].
The goal of vaccine-based cancer immunotherapy
approaches is to induce a tumor-speciﬁc immune response
that ultimately will reduce tumor burden by tipping the
balance from a protumor to an antitumor immune environ-
ment (Figure 1). This review discusses strategies employed
in the ﬁeld of cancer vaccines aimed at enhancing activation
of tumor-speciﬁc T-cells with concurrent reduction of
immunosuppression. Speciﬁcally, vaccine design, immune
adjuvants, and multimodal approaches using vaccines in
combination with other treatment modalities will be dis-
cussed here, with a particular emphasis on studies conducted
at the National Cancer Institute, NIH.
2. Vaccine Design: Choice of
Vaccine-DeliverySystem(s)
Depending on the vaccine-delivery system of choice, cancer
vaccines can elicit an immune response against an individual
or multiple tumor antigens. A list of the various types of
vaccine-delivery systems under investigation in the ﬁeld,
either at the preclinical or clinical stages, is presented in
Table 1. Multiple studies have demonstrated that combina-
tions of some of the strategies in the form of diversiﬁed
prime/boost regimens may enhance the outcome of the
intervention against the tumor [25]. Moreover, it has also
been shown that concurrent vaccination with two distinct
vaccine platforms targeting the same antigen can elicit a
more diverse population of antigen-speciﬁc T-cells thus
resulting in higher antitumor immunity [26].
Among the various types of vaccine delivery systems,
there are strategies based on the use of whole tumor cells,
dendritic cells-(DCs-) tumor cell fusions, or preparations
of DCs loaded with tumor protein lysates or tumor-derived
RNA (Table 1, left column). These vaccine platforms induce
an immune response against multiple tumor targets, either
known or unknown. Other vaccine modalities (Table 1,ri gh t
Table 1: Vaccine-delivery systems.
Vaccine-delivery systems
Immunization against multiple
antigens∗
Immunization against
speciﬁed antigen(s)
Cell-based Cell-based
Autologous whole-tumor cells DCs pulsed with peptide
Allogeneic whole-tumor cells Genetically-modiﬁed DCs
Genetically-modiﬁed tumor cells
DCs-tumor fusion Protein/Peptidebased
DCs loaded with tumor lysate Protein
Peptide
Agonist peptide
Antiidiotype MAb
Mab fusion proteins
DCs transfected with
tumor-derived RNA
Protein/Peptidebased
Tumor lysates Vector-based
Heat shock proteins-tumor peptides Plasmid DNA
Bacterial vectors
Listeria
Salmonella
Yeast vectors
Viral vectors
Adenovirus
Vaccinia
Avipox (fowlpox)
MVA
∗Vaccine formulation includes known and unknown antigens.
column)arebasedonthe previouscharacterizationof tumor
antigens to be used as “speciﬁed” targets in the vaccine
formulation.
3. Tumor Antigens
Tumor antigens are molecules either exclusively expressed in
the tumor cells, designated as “tumor-speciﬁc antigens”, or
molecules that are overexpressed in cancerous versus normal
tissues, designated as “tumor-associated antigens”. A com-
prehensive list of tumor antigens and their corresponding T-
cell epitopes can be found at [27, 28]. Table 2 shows a brief
list of selected examples for either type of antigen. Tumor-
speciﬁc antigens appear de novo after cancer cells acquire
mutations within the coding regions of certain genes, for
example the oncogene ras [29] and the tumor suppressor
p53 [30], or novel fusion proteins are generated as in the
case of the Bcr-Abl fusion in chronic myeloid leukemia [31].
Moreover, in tumors driven by infectious agents like human
papillomavirus (HPV) or Epstein-Barr virus (EBV), virally-
derived products become de novo targets of T-cell immune
responsesdirectedagainstthetumor.Themajorityoftumor-
associated antigens so far identiﬁed have a certain level of
expression in normal tissues and thus tolerance to these
antigens often exists.Journal of Biomedicine and Biotechnology 3
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Figure 1: Cancer vaccine strategies aimed at shifting the immune environment of a tumor from protumorigenic to antitumorigenic.
A strategy used by tumors to escape immune recog-
nition and destruction is the complete or partial loss of
an antigen(s) [17]. Both in experimental animal models
[32, 33], and in human cancer [34], it has been shown
that “antigen-negative tumor variants”, characterized by the
loss of the targeted antigen, can emerge subsequently to
an immune intervention. An approach to overcome this
problem is the targeting of “functionally relevant antigens”,
which are proteins with an essential role during tumor
initiation, growth, survival, or metastasis [35]. It can be
hypothesized that an immune intervention directed against
a functioning tumor antigen would greatly reduce the
emergence of antigen-negative variants, since cells that lose
the antigen will fail to grow, survive, or metastasize.
4.TargetingofMolecules thatControl
MetastaticDissemination
In order to achieve the various steps along the metastatic
cascade, epithelial tumor cells may need to undergo a
phenotypic conversion into mesenchymal cells via a process
designated as epithelial-to-mesenchymal transition (EMT)
[36]. The EMT program involves the downregulation of
epithelial proteins such as E-cadherin and cytokeratins,
and the upregulation of mesenchymal proteins including
Fibronectin, N-cadherin, and Vimentin. Various genes nor-
mally expressed in the early embryo have been implicated in
the control of the EMT triggered during tumor progression,
including Twist, Snail, Slug, Goosecoid,a n dSIP1 [36, 37].
The transcription factors encoded by these genes can impart
to tumor cells the traits of mesenchymal cells, including
motility and the ability to invade the extracellular matrix
(ECM). The expression of Twist, for example, has been
found to be elevated in various types of cancer, including
breast, prostate, and cervical cancer, with higher levels
of Twist protein being detected in prostate cancer tissues
of high Gleason score [38, 39]. Since the EMT process
Table 2: Human carcinoma antigens.
Carcinoma antigens∗
Tumor-speciﬁc antigens Tumor-associated antigens
Mutated molecules Carcinoembryonic antigen (CEA)
K-RAS Mucin 1 (MUC-1)
p53 Prostate-speciﬁc antigen (PSA)
Fusion molecules Prostate acid phosphatase (PAP)
BCR-ABL Prostate stem-cell antigen (PSCA)
Brachyury
Virally-derived molecules TERT
HPV-16 E6, E7 Wilm’s tumor 1 (WT1)
EBNA1, LMP1 and LMP2 Her-2/neu
Sox-2
NY-ESO-1
Cyclin D1
Mesothelin
Survivin
∗Included is only a partial list of antigens for human carcinomas.
appears to be a necessary step for tumor cells to initiate
the metastatic cascade [37, 40], interfering with EMT in
early stages of the disease is likely to prevent tumor cell
spreading and might also be eﬀective in treating established
metastatic lesions (Figure 2). An example of a tumor antigen
with a functionally relevant role in the EMT program is
the T-box transcription factor Brachyury, highly expressed
in various human tumors of epithelial origin, but not in
most human normal adult tissues [41]. It has been recently
demonstrated that Brachyury overexpression in epithelial
tumor cells induces an EMT, promoting the expression
of mesenchymal markers and downregulation of epithelial
markers, with concomitant increase in tumor cell migration
andinvasion[42].Additionally, stablesilencing ofBrachyury
expression in Brachyury-positive human carcinoma cells
has been shown to downregulate mesenchymal markers4 Journal of Biomedicine and Biotechnology
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Figure 2: The epithelial-to-mesenchymal transition (EMT) in tumor progression: an opportunity to target metastatic tumor cells. The
epithelial-to-mesenchymaltransition(EMT)anditsreverseprocess,designatedasmesenchymal-to-epithelialtransition(MET),areinvolved
in the progression of epithelial tumors towards metastasis. Vaccine strategies targeting molecules that control the EMT process, for example,
the transcription factor Brachyury, could be used to block tumor spreading.
and upregulate epithelial markers with simultaneous loss
of cell migration and ECM invasion. In vivo, Brachyury-
inhibited human tumor cells had a decreased ability to form
experimental lung metastases after intravenous injection,
as well as to disseminate from the primary, subcutaneous
tumor to the site of metastases [42]. A CD8 T-cell epitope
of Brachyury capable of expanding Brachyury-speciﬁc T-
cells from the peripheral blood of cancer patients was
recently identiﬁed [41]; Brachyury-speciﬁc T-cells have been
used to eﬃciently lyse Brachyury-positive tumor cells in
vitro. The successful expansion of T-cells directed against
the transcription factor Brachyury exempliﬁes the ability
of T-cell mediated immunotherapies to target (a) highly
conserved tumor proteins, and (b) tumor proteins irrespec-
tive of their cellular localization. Because of its relevant
role during tumor progression, Brachyury is an appealing
tumorantigenforinterventionsaimedatinterferingwiththe
metastatic spreading of tumor cells (Figure 2). Additionally,
the transcription factors Twist, Snail, and Slug, among
others, which are critically involved in the control of EMT
during tumor progression, could also be explored as novel
tumor antigens for the targeting of metastatic disease.
5. Antigen Cascade
A phenomenon observed with cancer vaccines is the induc-
tion of immune responses to tumor antigens that are not
present in the vaccine formulation. For example, it has
beenshownthatCEA-transgenicmicecuredofCEA-positive
tumors by a CEA/TRICOM vaccine regimen were able to
subsequently reject CEA-positive as well as CEA-negative
tumors, and that this eﬀect was mediated by the generation
ofspeciﬁcT-cellimmuneresponsesdirectedagainstgp70,an
antigenexpressedbythetumorbutnotpresentinthevaccine
[43]. The same phenomenon has also been reported in clini-
cal studies [44, 45]. Altogether these studies showed that the
immune response initiated against a tumor antigen included
in the vaccine formulation is then followed by cross-priming
and initiation of an “antigen cascade” that expands the
immune response to additional antigens expressed on the
tumor, thus potentiating antitumor immunity.
6. EnhancingActivation of Tumor-Speciﬁc
T-Cells: The Use of Costimulation in
the Vaccine Formulation
Optimal activation of T-cells is known to require at least
two signals. The ﬁrst signal is mediated by the interaction
betweenthepeptide/MHCcomplexonthesurfaceofantigen
presenting cells (APC) and the T-cell receptor (TCR) on
the surface of T-cells. The second signal, also designated
as costimulation, is mediated by the interaction between
accessory molecules located on the surface of the APC and
their corresponding ligand(s) on the T-cells [46]. Activation
via the TCR in the presence of adequate costimulatory
signals results in the clonal expansion, diﬀerentiation, and
expression of eﬀector functions by antigen-speciﬁc T-cells.
Optimization of themechanism ofT-cellactivationiscritical
to achieve a successful immune response to an antigen
included in a vaccine formulation. A list of various strategies
being explored in the ﬁeld of cancer vaccines to achieve
enhanced antitumor immune responses is presented in
Table 3. One of them is the delivery of a single or multiple
costimulatory molecules along with the tumor antigen as
part of the vaccine formulation. One of the most studied T-
cell costimulatory molecules is B7-1 [47, 48]. In preclinical
studies it has been shown that mice immunized with an
admixture of recombinant vaccinia (rV-) viruses encoding
for a tumor antigen (rV-CEA or rV-MUC-1) and the
costimulatory molecule B7-1 (rV-B7-1) generate eﬀective
antigen-speciﬁc T-cell immune responses that translate into
successful antitumor immunity [49]. Furthermore, it was
demonstrated that combinations of various costimulatoryJournal of Biomedicine and Biotechnology 5
molecules act synergistically to further enhance antigen-
speciﬁc T-cell responses. Using recombinant vaccinia and
fowlpox viruses encoding for the tumor antigen CEA and
three diﬀerent costimulatory molecules (B7-1, ICAM-1,
LFA-3, designated as TRICOM), T-cell responses against
the tumor antigen were further enhanced above the level
observed when only one costimulatory molecule was used
[50]. In preclinical studies with human T-cells in vitro,
enhanced activation of antigen-speciﬁc T-cells was observed
against DCs modiﬁed by infection with rF-TRICOM [51].
Moreover, the same vector was successfully used to enhance
the antigen-presentation potency of freshly isolated B cells,
resulting in enhanced activation of antigen-speciﬁc T-cell
responses in vitro [52]. Results from a Phase II randomized
clinical trial in 125metastatic prostate cancer patients were
recently reported [53]; patients were randomized to receive
either a vaccine regimen consisting of two recombinant viral
vectors each encoding for prostate speciﬁc antigen (PSA)
and the TRICOM molecules (rV-PSA/TRICOM and rF-
PSA/TRICOM), or control empty vector (control arm). The
results from this trial demonstrated a 44% reduction in
the death rate and an 8.5 month improvement in median
overall survival (OS) in men in the vaccine compared to
the control arm [53]. Additionally, NCI also reported the
results from a randomized Phase II trial in 32 patients with
metastatic castrate-resistant prostate cancer, who received a
prime with rV-PSA/TRICOM and booster vaccinations with
rF-PSA/TRICOM. Twelve of 32 patients showed declines
in serum PSA post-vaccination; patients with greater PSA-
speciﬁc T-cell responses showed a trend toward enhanced
survival. In general, there was evidence of enhanced median
overallsurvival,particularlyamongpatientswithmoreindo-
lent type of disease [54]. Overall, cancer vaccine strategies
incorporating costimulatory molecules have demonstrated
the generation of antitumor immunity and evidence of
clinical beneﬁt in cancer patients.
7. The Use of Cytokinesas Vaccine Adjuvants
7.1. Cytokines that Aﬀect the APCs. Biological adjuvants are
agents generally used for improving the immunogenicity
of an antigen in a vaccine formulation. Several cytokines
have the ability to enhance immune responses by either
(a) promoting the diﬀerentiation, activation, or recruit-
ment of APC, therefore enhancing antigen presentation
and activation of antigen-speciﬁc T-cell responses, or (b)
by directly acting on various subsets of T-cells. Within
the ﬁrst group, one of the most studied cytokines is the
granulocyte-macrophage colony-stimulating factor (GM-
CSF). It has been demonstrated in preclinical studies that
subcutaneous injections of GM-CSF at the vaccination site
can signiﬁcantly increase the inﬁltration of DCs in regional
lymph nodes that drain the site of vaccination [55, 56]. In
several preclinical studies, tumor cells or DCs genetically
engineered to secrete biologically active GM-CSF have been
used to generate a systemic antitumor immune response
[57, 58]. The use of GM-CSF at high doses, however, could
be detrimental in the context of vaccines since it may result
Table 3: Strategies to enhance antitumor T-cell responses∗.
Strategy
Use of costimulation in vaccine formulation
Cytokines
Eﬀect on APC (GM-CSF)
Eﬀect on T-cells (IL-2, IL-7, IL-15, IL-12)
Radiation
Chemotherapy
Small molecule targeted therapies
Inhibition of coinhibitory signals
At the tumor site (B7-H1, B7-H4)
Directly on T-cells (CTLA-4)
Depletion/inhibition of Treg cells
Inhibition of immunosuppressive cytokines
AntiTGF-β
AntiVEGF
∗Only a partial list is included here.
in immune suppression via the activation and expansion
of myeloid-derived suppressor cells [59]. In the clinical
setting, two placebo-controlled Phase III trials in patients
with hormone-refractory prostate cancer, for example, have
been performed with an autologous DC-based vaccine, des-
ignatedSipuleucel-T,whichisgeneticallymodiﬁedtoexpress
prostatic acid phosphatase (PAP) as a tumor antigen, and
GM-CSF. Results from the initial trial with 127 patients [60]
demonstrated a 4.5-month improvement in median survival
in thevaccineversusplacebogroup, thoughwithoutmeeting
the primary endpoint of time to progression. Results from
a subsequent Phase III, placebo-controlled trial measuring
overall survival as the primary endpoint have been recently
reported [61], indicating a statistically signiﬁcant survival
advantage in patients in the vaccine versus placebo group.
7.2. Cytokines that Aﬀect the T-Cell Compartment. The
secondgroupincludescytokinesthatdirectlyaﬀecttheT-cell
compartment by promoting T-cell proliferation, activation,
and eﬀector function. Among these, the cytokines IL-2 [62,
63], IL-7 [64], IL-15 [65, 66], and IL-12 [67] are currently
underinvestigationtoenhanceantitumorimmuneresponses
elicited by a vaccine. The most used of these cytokines is
IL-2, a T-cell growth factor which, as a single agent, has
demonstrated clinical responses in patients with metastatic
renal cell carcinoma [68]a n dm e t a s t a t i cm e l a n o m a[ 69]. A
disadvantage, however, in the use of IL-2 therapy in vivo,
particularly with high-dose IL-2, is the rate of associated
toxicities [70]. Moreover, IL-2 mediates not only the pro-
liferation of activated, eﬀector T-cells and NK cells, but
also the development and homeostasis of regulatory T-cells
(Tregs), which constitutively express elevated levels of the
IL-2R alpha (CD25) [71]. In vitro, IL-2 has also been used
to expand tumor-speciﬁc T-cells to be used for adoptive
immunotherapy [72].
The cytokines IL-15 and IL-7 are also T-cell growth
factors; their function, however, is diﬀerent to that of IL-2 in6 Journal of Biomedicine and Biotechnology
vivo. IL-15is necessaryfor the development andhomeostasis
of memory CD8 T-cells and NK cells [65]. It has also been
demonstrated a role for IL-15 in the induction of long-lived,
high avidity CD8 T-cells [73, 74] and, unlike IL-2, there is no
roleforIL-15ontheproliferationofTregs.Uptodate,studies
with IL-15 as an adjuvant for cancer vaccine strategies have
onlybeenconductedinpreclinicalmodels,withencouraging
results [67]. The cytokine IL-7, another T-cell growth factor,
targets a diﬀerent population of T-cells, promoting the
expansion of na¨ ıve T-cells and thus increasing the diversity
of T-cell repertoire after lymphopenia [64, 65]. IL-7 has also
demonstrated positive results as an adjuvant cytokine for
cancer vaccine interventions in preclinical studies [67].
Another cytokine that is under investigation as a vaccine
adjuvant is IL-12, which promotes Th1 polarization, prolif-
eration of activated T-cells and NK cells, and cell-mediated
immunity. IL-12 has been shown to have potent antitumor
eﬀects in preclinical models [75] .I nh u m a n s ,h o w e v e r ,t h e
systemic delivery of IL-12 has resulted in elevated toxicities
[76], hence leading towards the investigation of alternative
modes for local delivery of IL-12. For example, in preclinical
studies, a coformulation of IL-12 with chitosan intravesically
delivered was well tolerated and very eﬃc i e n ta tc u r i n g
mice with superﬁcial bladder cancer. A durable antitumor
immune response was also generated in mice receiving
IL-12/chitosan, providing them with complete protection
from intravesical tumor rechallenge [77]. Overall, the use
of cytokines as vaccine adjuvants to enhance the immune
response to a tumor is a very promising and active ﬁeld of
investigation. Current research is focused on understanding
the proper ways of delivery for each particular cytokine
in order to maximize the immune adjuvant eﬀects while
reducing potential toxicities, when used in combination with
various types of vaccine platforms.
8 .V ac c in eP l usR ad iatio n
As it was mentioned above, a mechanism by which tumor
cells escape immune recognition and attack is through the
downregulation of tumor antigens, MHC expression, or
various components of the antigen processing/presentation
machinery. A strategy to overcome these obstacles is the use
of radiation on tumor cells. Radiation is the standard of
care for many types of cancer because of its direct cytotoxic
eﬀect on the tumor or its palliative eﬀects on the patient. It
has been recently reported that local irradiation of tumors
with doses insuﬃcient to induce tumor cell death could
result in changes on the phenotype of the tumor cells that
include the upregulation of MHC, Fas, ICAM-1, and various
tumor associated antigens [78–80]. As a result of these
changes, irradiated tumor cells are more susceptible to T-
cell mediated immune attack. In preclinical studies with
a murine colon carcinoma tumor model, sublethal, local
tumor irradiation signiﬁcantly improved the therapeutic
eﬃcacy of a recombinant rV-/rF-CEA/TRICOM vaccine
regimen against CEA-positive tumors in CEA-transgenic
mice [81], while radiation alone or vaccine alone had no
eﬀect on tumor growth. In the clinical setting, the approach
has been investigated in a phase II clinical trial in patients
with localized prostate cancer, randomized to receive a PSA-
basedpoxviralvaccineplusradiotherapyversusradiotherapy
alone [82]. The results from this trial indicated increases in
PSA-speciﬁc T-cell responses of at least 3-fold in patients
in the combination arm; the authors also reported evidence
of de novo generation of T-cells to well-described prostate-
associated antigens not found in the vaccine, providing
indirect evidence of immune-mediated tumor killing. These
studies thus demonstrated a new paradigm for the use of
local tumor irradiation in combination with active vaccine
therapy to elicit an eﬀective antitumor immune response.
9.Vaccines Plus CytotoxicDrugs
Because of the widespread use of chemotherapy for the
treatment of most malignancies, it is rational to design
combinatorial approaches using vaccines plus standard
chemotherapeutic agents. Like radiotherapy, the use of
various types of chemotherapy in combination with vaccines
has resulted in enhanced antitumor immune responses.
Although the mechanisms involved vary among the various
types of cytotoxic drugs employed, in general, drugs can:
(a) induce “immunogenic death” of tumor cells, leading to
activation of DCs followed by antigen presentation to T-
cells [83, 84], or (b) modulate the phenotype of the tumor
cells making them more susceptible to immune-mediated
killing. For example, it has been shown that treatment of
human colon carcinoma cell lines with 5-ﬂuorouracil or
cisplatin enhances their lytic sensitivity to antigen-speciﬁc
CD8+ cytotoxic T lymphocytes, by inducing expression of
ICAM-1 and Fas [85]. Similarly, treatment of renal cell
carcinoma cells with subtoxic concentrations of adriamycin
has been shown to upregulate the expression of ICAM-1
and LFA-3, as well as to enhance T-cell mediated killing,
Fas-mediated, and TRAIL-mediated killing of tumor cells
[86]. Taxanes, on the other hand, are a widely used type
of chemotherapeutic agents known to have various eﬀects
on the immune system, promoting macrophage activation
and release of inﬂammatory cytokines at the tumor site,
thus enhancing tumor lysis [87]. In preclinical studies with
CEA-transgenic mice transplanted with CEA-positive tumor
cells, enhanced antitumor eﬀect was achieved by using a
combination of a rV-/rF-CEA/TRICOM vaccine regimen
plus docetaxel, compared to that of vaccine or docetaxel
alone [88]. In preclinical models as well, cyclophosphamide,
doxorubicin, and paclitaxel have all been shown to enhance
the antitumor immune response elicited with a GM-CSF-
secreting, HER2/neu-expressing whole-tumor cell vaccine in
tumor bearing neu-transgenic mice [89]. The authors were
able to demonstrate that the increased antitumor eﬀects in
the combination group (vaccine plus drugs) were due to
enhanced vaccine eﬃcacy rather than a direct cytolytic eﬀect
of the drugs on cancer cells [89].
Altogether, these studies demonstrated that, if used in
appropriate schedule and at the correct doses, chemothera-
peutic agents could enhance antitumor responses when used
in combination with cancer vaccine modalities. Therefore,Journal of Biomedicine and Biotechnology 7
further studies investigating optimum schedules and dosing
for various chemotherapeutic agents are needed in order to
optimize the use of diﬀerent cytotoxic agents in combination
with cancer vaccines.
10.Vaccine Plus SmallMolecule
Targeted Therapies
As the molecular pathways involved in the various steps of
carcinogenesis and tumor progression are being elucidated
with the advent of sophisticated genetic and molecular
techniques, a novel group of therapeutic cancer drugs aimed
at inhibiting speciﬁc molecular pathways is emerging, desig-
nated as small molecule targeted therapies. These drugs are
also now being investigated for their immune-modulatory
functions to be potentially used in combination with cancer
vaccines. For example, the anticancer agent lenalidomide
(Revlimid, Celgene Corp., NJ, USA), which is FDA approved
for the treatment of patients with multiple myeloma, has
been shown to have several immune-modulatory eﬀects
that include costimulatory eﬀects on CD3-activated T-cells,
augmentation of NK cell cytotoxicity, and suppression of
Treg cells proliferation and function [90, 91]. Results from a
study combining a small molecule BCL-2 inhibitor and a rV-
/rF-CEA/TRICOM vaccine regimen were recently reported
[92]. It has been shown that, when administered after the
vaccine, the BCL-2 inhibitor GX15-070 was able to increase
the intratumoral ratio of activated, CD8+ T eﬀector to Treg
cells, thus resulting in signiﬁcant reduction of pulmonary
tumor nodules in a mouse model of experimental lung
tumors [92]. As with chemotherapeutic agents, the use of
small molecule targeted therapies could also be associated
with potential toxicities and, in particular, with negative
eﬀects on the immune compartment. Thus, further studies
investigating optimum schedules and dosing for various
small molecule targeted drugs are needed in order to
optimize their use in combination with cancer vaccines.
11. Inhibition of Coinhibitory Signals
An alternative strategy to enhance the outcome of an
antitumor immune approach is to eliminate negative signals
imparted to T-cells by coinhibitory molecules such as B7-
H1, B7-H4, and cytotoxic T-lymphocyte antigen-4 (CTLA-
4), among others. B7-H1 is constitutively expressed in many
types of human tumors and has been shown to promote
evasion of tumor immunity by promoting apoptosis of
activated eﬀector T-cells [18] and tumor resistance to T-
cell mediated lysis [93]. In preclinical studies, blockade of
B7-H1 with a speciﬁc monoclonal antibody has resulted in
enhanced antitumor immune responses [93, 94]. B7-H4 is
another member of the B7 family that has been implicated
as a negative regulator of T-cell immunity [95]. It has been
demonstratedthatB7-H4caninhibitT-cellproliferationand
IL-2 production, and that blockade of B7-H4 in preclinical
animal models results in enhanced cytotoxic T-cell responses
against an alloantigen [19]. The expression of B7-H4 has
been observed in many types of human cancer, such as breast
[96], ovary [97], and lung [98]. In renal cell carcinoma, its
expression has been correlated with more aggressive tumors,
particularly in those cases where both B7-H1 and B7-H4
are aberrantly overexpressed [99]. Therefore, blocking of
molecules such as B7-H1 and B7-H4 expressed on tumor
cells can reduce coinhibitory signals directly at the site of the
tumor (Table 3), resulting in enhanced antitumor immune
responses.
Ad i ﬀerent strategy involves blocking of inhibitory
moleculesdirectlyexpressedonT-cells.AnexampleisCTLA-
4, a negative regulator of T-cell activation, which is expressed
on the T-cells and, like its homolog CD28, binds to B7 on
the surface of the APC. Binding of CTLA-4 to B7 initiates a
negative signal cascade that leads to downregulation of the
T-cell response [100, 101]. The blockade of CTLA-4 with
speciﬁc, monoclonal antibodies (mAb) has been explored
as a monotherapy or in combination with vaccine therapy
in preclinical and clinical studies. In preclinical studies,
the use of antiCTLA-4 mAb as a monotherapy has shown
antitumoractivitywithimmunogenictumors[100,101],but
not with poorly immunogenic tumors, such as MC38 [102].
In combination with vaccines, antiCTLA-4 mAb has been
used to enhance antitumor T-cell responses elicited by the
vaccine, thus resulting in eﬀective antitumor eﬀects [102]. In
the clinic, antiCTLA-4 has been used also as a monotherapy
or in combination with other immune-mediated anticancer
modalities [103]. Results from a phase I clinical trial with
antiCTLA-4 mAb (ipilimumab) in patients with metastatic
melanoma or renal cell cancer recently reported a 14%
response rate and multiple, and at times severe, immune-
mediated toxicities such as nephritis, panhypophysitis, and
enterocolitis, among others [104, 105], this last point
constituting a potential disadvantage of the approach.
12. Depletion/Inhibitionof Regulatory T-Cells
Naturally occurring regulatory T (Treg) cells, characterized
by expression of IL-2R alpha, the transcription factor Foxp3,
CTLA-4, and glucocorticoid-induced tumor necrosis factor
(TNF) receptor (GITR), constitute 5% to 10% of peripheral
CD4+ T-cells [11, 106]. Treg cells represent an important
mechanism of peripheral T-cell tolerance through their
inhibitionofself-reactiveeﬀectorT-cells[107],andhavealso
been implicated in the lack of eﬀective antitumor immunity
as the number of Treg cells are increased in the tumors
and peripheral blood of cancer patients [108, 109]. Previous
s t u d i e si ns e v e r a lm o d e l so fm o u s et u m o r sh a v ed e m o n -
strated that deletion of Treg cells by using an antiCD25
mAb enhanced the development of antitumor immunity
leading to tumor rejection [110, 111]. Furthermore, it has
been previously shown that antigen-speciﬁc T-cell responses
induced by poxviral vaccines can be augmented by simul-
taneous administration of antiCD25 mAb in mice [112].
Among alternative modalities that can be used in humans to
delete Treg cells is denileukin diftitox, (DAB389IL-2), a fusion
protein of IL-2 and diphtheria toxin, previously shown in
mouse preclinical studies to reduce Treg cells and to enhance
antigen-speciﬁc immune responses induced by poxviral8 Journal of Biomedicine and Biotechnology
vaccines [113]. A potential drawback of both approaches
is that activated, eﬀector T-cells also transiently upregulate
the expression of CD25 on their cell surface, therefore being
at risk of depletion by strategies that target CD25. In the
clinic, denileukin diftitox was previously shown to reduce
Treg cells and to lead to objective clinical responses in
patients with ovarian cancer [12, 114]. Moreover, antitumor
immunotherapy approaches combining denileukin diftitox-
mediated deletion of Treg cells followed by vaccination
with RNA-transfected DCs, tumor antigen peptides, or DCs
modiﬁed by infection with rF-CEA(6D)/TRICOM, have
been shown to improve tumor-speciﬁc T-cell responses in
patients with renal cell cancer, melanoma, or CEA-positive
malignancies, respectively, [115–117].
13. InhibitionofImmunosuppressiveCytokines
Tumors can also evade immunosurveillance by directly
secreting a number of inhibitory cytokines or by inducing
various types of immune cells to secrete cytokines associated
with reduced immune responses. One of these cytokines
is the transforming growth factor beta (TGF-β), which
c a nb ed i r e c t l ys e c r e t e db ym a n yt y p e so ft u m o rc e l l s ,
including breast, prostate, colon, liver, lung, and melanomas,
among others [118, 119]. TGF-β exerts its negative eﬀects
on T-cells, NK cells, macrophages and DCs [120]. Several
preclinical studies have demonstrated that blockade of TGF-
β can reverse the immunosuppressive eﬀects of the tumor
microenvironment. For example, a small molecule TGF-β
inhibitor was used in a mouse tumor model to rescue the
functionality of inﬁltrating CD8+ T-cells (TILs), which are
usually hyporesponsive [121]. Recently, it was also reported
a synergistic improvement of a peptide vaccine modality in
combination with a monoclonal antibody against TGF-β,i n
a murine tumor model [122]. Although no adverse eﬀects
have been observed in studies so far conducted, the dual
role of TGF-β on normal versus tumor cells, where it can
function as a suppressor or promoter of tumor development,
respectively, may constitute a potential problem for this
approach and indicates the necessity for detailed studies
aimed at optimizing the use of antiTGF-β reagents while
minimizing the potential for adverse eﬀects.
Another cytokine that has a negative impact on the
development of antitumor T-cell responses is the vascular-
endothelial growth factor (VEGF). A major role of VEGF
is to induce the process designated as tumor angiogenesis,
which involves the development of an adequate tumor
vasculature that will support a blood supply to the growing
tumor [123, 124]. Additionally, VEGF contributes to tumor
immune escape by inducing the development of immune
cell populations with immunosuppressive functions, like
immatureDCs[24]andtherecruitmentoftumor-associated
macrophages (TAM) to the tumor stroma [13, 14, 125].
Strategies aimed at inhibiting VEGF or its receptors, there-
fore, will not only disrupt the tumor vasculature thus
impairing tumor growth, but will also improve antitumor
immunity by eliminating inhibitory cell populations, result-
ing in enhanced responses to cancer vaccines. In preclinical
studies, for example, an antiVEGF antibody enhanced the
eﬃcacy of a peptide-pulsed DC-based vaccine that resulted
in prolonged and pronounced antitumor eﬀect[126]. There-
fore, inhibition of VEGF may be a valuable adjuvant in
the immunotherapy of cancer. A disadvantage of antiVEGF
therapies in the clinic has been the emergence of toxicities
thatincludedwoundhealingcomplicationsaswellasadverse
vascular eﬀects.
14. Conclusions
Progress in understanding the molecular mechanisms that
govern immune activation as well as the mechanisms
used by tumor cells to evade surveillance by the immune
system are advancing the development of immune-mediated
therapies that could be eﬀectively used against a range
of human cancers. The combination of cancer vaccines
with other therapeutical modalities, in particular established
therapies such as radiation and chemotherapy, as well as
small molecule targeted therapies, provides an opportunity
to further improve the outcome of vaccine interventions
against cancer. Moreover, several studies also indicated that
patients who receive a cancer vaccine have an enhanced
outcome to subsequent therapies, thus providing another
possible approach for the use of cancer vaccines prior to
other cancer interventions. A prospective randomized trial
is being initiated to substantiate these ﬁndings. Unlike other
modalities, cancer vaccines have so far demonstrated no
associated toxicities and therefore their use could not only
result in improved patient survival but also in improvements
in quality of life.
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